These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25744866)

  • 1. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
    Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
    Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
    Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
    N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
    Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
    J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
    Liu Q; Kan Y; Zhao Y; He H; Kong L
    Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate.
    Owusu-Brackett N; Johnson R; Schindel DT; Koduru P; Cope-Yokoyama S
    Cancer Genet; 2013; 206(9-10):353-6. PubMed ID: 24290361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib.
    Kiratli H; Uzun S; Varan A; Akyüz C; Orhan D
    J AAPOS; 2016 Jun; 20(3):260-3. PubMed ID: 27312965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
    Mikes RE; Jordan F; Hutarew G; Studnicka M
    Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.
    Ono A; Murakami H; Serizawa M; Wakuda K; Kenmotsu H; Naito T; Taira T; Koh Y; Ohde Y; Nakajima T; Endo M; Takahashi T
    Lung Cancer; 2016 Sep; 99():151-4. PubMed ID: 27565932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Myofibroblastic Tumor Driven by Novel
    Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
    J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
    Kaneda H; Okamoto I; Nakagawa K
    J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
    [No Abstract]   [Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase positive inflammatory myofibroblastic tumor of the urachus: A rare neoplasm in an unusual location.
    Venkatesh K; Madhusudhan HR
    Indian J Pathol Microbiol; 2016; 59(1):93-5. PubMed ID: 26960648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.
    Li Y; Chen X; Qu Y; Fan JM; Li Y; Peng H; Zheng Y; Zhang Y; Zhang HB
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1459-1462. PubMed ID: 31805529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
    Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC
    J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446
    [No Abstract]   [Full Text] [Related]  

  • 17. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L; Solomon B
    Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.